Protagonist Therapeutics Inc Stock
Pros and Cons of Protagonist Therapeutics Inc in the next few years
Pros
Cons
Comments
News
Takeda Pharmaceutical Q1 Earnings Call Highlights
Takeda Pharmaceutical (NYSE:TAK) said its first-quarter fiscal 2026 results were in line with its full-year outlook as growth from
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit
Hedge fund BVF reported a full exit from Protagonist Therapeutics (NASDAQ:PTGX) in its February 17, 2026, SEC filing, selling 2,560,916 shares worth an estimated $170.12 million.
According to its
Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance
On Feb. 6, 2026, William D. Waddill, a director at Protagonist Therapeutics (NASDAQ:PTGX), exercised his stock options and immediately sold 20,000 shares, generating a transaction value of


